PILA PHARMA AB

PILA PHARMA AB, a Swedish biotech company, announced a recent interview with Helge Larsen from ProInvestor, Denmark's largest online forum for investors in biotechnology and pharmaceutical stocks. The interview, conducted in Danish, featured founder and CSO Dorte X. Gram discussing the company's development of a novel oral treatment for obesity and diabetes using a TRPV1 antagonist. The recording is available online, with an English subtitled version forthcoming. PILA PHARMA is listed on Nasdaq First North Growth Market, Sweden, and focuses on developing treatments for obesity, type 2 diabetes, erythromelalgia, and abdominal aorta aneurysm. Their lead candidate, XEN-D0501, has shown promise in clinical trials for improving insulin response and reducing cardiovascular biomarkers. The company is preparing for further clinical trials to assess safety and efficacy. PILA PHARMA also collaborates with Uppsala University on research for abdominal aorta aneurysms, where XEN-D0501 has shown potential in preclinical studies.

PILA PHARMA AB will participate in a 1-on-1 interview with Helge Larsen from ProInvestor on June 5, 2025. The interview will feature Founder and CSO Dorte X. Gram discussing the company's development of a novel oral treatment for obesity and diabetes using a TRPV1 antagonist. The discussion will cover topics such as the mode of action of TRPV1 antagonists, data supporting their use for metabolic diseases, and progress on their lead candidate, XEN-D0501. The interview will be conducted in Danish and transcribed to English, with the recording available on June 6, 2025. PILA PHARMA is a Swedish biotech company focused on developing TRPV1 antagonists for treating type 2 diabetes and other inflammatory diseases. Their lead candidate, XEN-D0501, has shown promising results in clinical trials for obesity and diabetes, and holds orphan drug designation for erythromelalgia. XEN-D0501 has demonstrated efficacy in reducing glucose intolerance and body weight gain in preclinical studies and has a good safety profile. The company is preparing for further clinical trials to assess the safety and efficacy of XEN-D0501. PILA PHARMA is also involved in research for treating erythromelalgia and abdominal aorta aneurysm, with ongoing studies and collaborations to explore the potential of XEN-D0501 in these areas. The company aims to address unmet needs in obesity and diabetes treatment, with a focus on developing accessible oral therapies.

PILA PHARMA AB held its annual general meeting on April 29, 2025, in Malmö, Sweden, where key decisions were made. The company's financial statements for 2024 were approved, and it was decided that no dividend would be distributed for that year. The board and CEO were granted discharge from liability for 2024. The meeting re-elected board members Dorte Xenia Gram, Richard Busellato, Lasse Richter Petersen, and Julie Waras Brogren, with Dorte Xenia Gram continuing as chair. Deloitte AB was re-elected as auditor, with Maria Ekelund as the lead auditor. The nomination committee will include Dorte Xenia Gram and Niels Raaschou. The board was authorized to issue new shares or financial instruments until the next annual meeting. PILA PHARMA is a Swedish biotech company focused on developing TRPV1 antagonists for treating type 2 diabetes and other inflammatory diseases. Its main asset is XEN-D0501, which has shown promise in clinical trials for obesity and type 2 diabetes. The company plans further trials to determine the maximum tolerable dose and assess safety and efficacy. PILA PHARMA also explores treatments for erythromelalgia and abdominal aorta aneurysm, with ongoing research collaborations and development plans.

PILA PHARMA AB, a Swedish biotech company, invites investors and interested parties to upcoming events where they will present their work on innovative treatments for obesity, diabetes, and other conditions. These events include a panel debate in Malmö on April 28, 2025, the Vator Life Science Summit in Stockholm on May 14, 2025, and the AktieInfo Investor Evening in Copenhagen on May 19, 2025. The company focuses on developing TRPV1 antagonists, specifically XEN-D0501, for treating type 2 diabetes, obesity, erythromelalgia, and abdominal aorta aneurysm. XEN-D0501 has shown promising results in clinical trials, demonstrating good tolerability and efficacy. PILA PHARMA continues to advance its research and development efforts, with plans for further clinical trials and ongoing collaborations. The company is publicly traded on Nasdaq First North Growth Market in Sweden.

PILA PHARMA AB (publ) reminds shareholders that April 23 is the last day to register for the Annual General Meeting on April 29, 2025, in Malmö, Sweden. Shareholders can attend in person or vote via proxy. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 antagonists for treating type 2 diabetes and other diseases. Their development candidate, XEN-D0501, has shown promise in clinical trials and has potential applications in obesity, diabetes, erythromelalgia, and abdominal aorta aneurysm. The company is preparing for further clinical trials to evaluate safety and efficacy. Obesity and diabetes are significant global health issues, and PILA PHARMA is working on potential treatments for these conditions. Erythromelalgia is a rare disease causing pain and redness, with no current treatments available. Abdominal aorta aneurysm affects many globally, and PILA PHARMA's research has shown potential in reducing its growth.

Aktieägarna i PILA PHARMA AB kallas till årsstämma den 29 april 2025 i Malmö. För att delta måste aktieägare vara registrerade i aktieboken senast den 17 april och anmäla sig senast den 23 april. Vid stämman kommer olika ärenden att behandlas, inklusive godkännande av årsredovisningen, beslut om vinstdisposition och ansvarsfrihet för styrelsen. Valberedningen föreslår omval av styrelseledamöter och revisor. Styrelsen föreslår att ingen utdelning lämnas för 2024 och begär bemyndigande att emittera nya aktier. Handlingar inför stämman finns tillgängliga på bolagets huvudkontor och hemsida. Personuppgifter hanteras enligt dataskyddsförordningen.

PILA PHARMA AB is inviting investors to an online webinar on February 27, 2025, where CEO Gustav H. Gram will discuss the company's 2024 second half-year report and their TRPV1 antagonist for obesity and related disorders. The company, listed on Nasdaq First North Growth Market, is a Swedish biotech firm focusing on developing TRPV1 antagonists as treatments for type 2 diabetes, obesity, and other inflammatory diseases. Their lead compound, XEN-D0501, has shown promise in clinical trials for obesity and type 2 diabetes, and has been granted orphan drug designation for erythromelalgia. PILA PHARMA is also exploring its use for abdominal aorta aneurysm, with preclinical success in reducing aneurysm growth in mice. The company is preparing for further clinical trials to assess safety and efficacy in these conditions.

PILA PHARMA AB has announced the completion of a study by Professor Dick Wågsäter's Research Group at Uppsala University, which showed that their TRPV1 antagonist, XEN-D0501, significantly reduced the growth of Abdominal Aorta Aneurysm (AAA) in mice. This establishes a preclinical proof-of-concept for the drug's potential to reduce chronic inflammation leading to cardiovascular diseases, including aorta dilatation. The study revealed that XEN-D0501 decreased aorta dilatation by over 50% compared to placebo, nearly inhibiting aneurysm development in the model. The results await further validation before publication. PILA PHARMA focuses on developing TRPV1 antagonists for type 2 diabetes and other inflammatory diseases. XEN-D0501 has shown good safety profiles in previous trials and is being prepared for further clinical studies. The company also holds patents for using TRPV1 antagonists in treating obesity and diabetes. PILA PHARMA is based in Malmö, Sweden, and is listed on the Nasdaq First North Growth Market.

PILA PHARMA AB has appointed Hampus Darrell as its new Chief Financial Officer (CFO). Hampus brings extensive experience in accounting and financial management, having worked in various roles at KPMG and E.ON, and as CFO at Setterwalls Advokatbyrå. He holds a Master of Science in Business and Economics from Lund University and became a Swedish Certified Public Accountant in 2005. Hampus will join PILA PHARMA part-time from December 2024, succeeding Elna Lembrér Åström, who is retiring. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 antagonists for treating type 2 diabetes and other inflammatory diseases. The company owns the development candidate XEN-D0501, which has shown promise in clinical trials. PILA PHARMA is working on projects related to type 2 diabetes, erythromelalgia, and abdominal aorta aneurism. The company also collaborates with Uppsala University to study the effects of XEN-D0501 on abdominal aorta aneurism growth in mice.

PILA PHARMA AB has announced the start of a study in collaboration with Professor Dick Wågsäter's research group at Uppsala University. The study aims to investigate the effects of PILA PHARMA's lead molecule, XEN-D0501, on the growth of Abdominal Aorta Aneurism (AAA) in mice. The hypothesis is that XEN-D0501 may reduce inflammation leading to cardiovascular diseases, potentially preventing AAA's progression. PILA PHARMA will co-sponsor the research, with the Research Group retaining publication rights after patenting. If successful, this study could lead to human trials. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 antagonists for type 2 diabetes and other inflammatory diseases. XEN-D0501 has shown promise in previous trials for diabetes and obesity, and the company is planning further clinical trials to explore its potential benefits.